Neurocognitive Change in the Era of HIV Combination Antiretroviral Therapy: The Longitudinal CHARTER Study

Heaton, Robert K.; Franklin, Donald; Deutsch, Reena; Letendre, Scott; Ellis, Ronald J.; Casaletto, Kaitlin B.; Marquine, María J.; Woods, Steven Paul; Vaida, Florin; Atkinson, J. Hampton; Marcotte, Thomas D.; McCutchan, J. Allen; Collier, Ann C.; Marra, Christina M.; Clifford, David B.; Gelman, Benjamin B.; Sacktor, Ned; Morgello, Susan; Simpson, David M.; Abramson, Ian; Gamst, Anthony; Fennema-Notestine, Christine; Smith, Davey M.; Grant, Igor

doi:10.1093/cid/ciu862

Cited by 352 publications

(323 citation statements)

References 27 publications

Supporting

Mentioning

296

Contrasting

Unclassified

Order By: Relevance

“…This frequency of HAND is somewhat lower than the estimates for HAND in other large cohort studies that report a HAND prevalence of 47% excluding severely confounded cases. 9 Our study excluded additional potentially contributing confounders for cognitive impairment and that could account for the lower prevalence rate of HAND. Demographic differences between the MACS and CHARTER cohorts (e.g., the MACS cohort has a higher mean education and the CHARTER cohort includes both men and women) could also account for these differences.…”

Section: Activities Of Daily Living: the Macs Uses An Adaptation Ofmentioning

confidence: 99%

Prevalence of HIV-associated neurocognitive disorders in the Multicenter AIDS Cohort Study

et al. 2016

View full text Add to dashboard Cite

Objective: To evaluate the frequency of HIV-associated neurocognitive disorder (HAND) in HIV1 individuals and determine whether the frequency of HAND changed over 4 years of follow-up. Methods:The Multicenter AIDS Cohort Study (MACS) is a prospective study of gay/bisexual men.Beginning in 2007, all MACS participants received a full neuropsychological test battery and functional assessments every 2 years to allow for HAND classification.

show abstract

Section: Activities Of Daily Living: the Macs Uses An Adaptation Ofmentioning

confidence: 99%

Prevalence of HIV-associated neurocognitive disorders in the Multicenter AIDS Cohort Study

et al. 2016

View full text Add to dashboard Cite

show abstract

“…Moreover, we recently showed that aviremic patients with ANI do not display the same pattern of immune activation than MND, suggesting that this definition is not stringent and not represent overt disease, or that it is a pre-clinical condition of more severe forms of impairment [34]. However, others have showed that patients with ANI have higher risks to deteriorate over time than unimpaired subjects [45][46][47]. Therefore, despite the ongoing debates about its real role, diagnosing ANI is one of main priorities and difficulties in the management of HAND in the cART era.…”

Section: Discussionmentioning

confidence: 99%

Evaluation of Three Brief Screening Tests for Older Patients with Mild HIVAssociated Neurocognitive Disorders in the cART Era

Vassallo¹,

Barbaud²,

Fabre³

et al. 2017

J Neurol Neurophysiol

View full text Add to dashboard Cite

show abstract

“…Maintain close collaboration of HIV physician with psychiatrist Table 1: Recommendations for overcoming challenges in the management of psychiatric comorbidities in HIV [32][33][34][35][36][37][38][39].…”

Section: Discussionmentioning

confidence: 99%

Neuropsychiatric Complexities in the HIV Patient – Clinical Challenges beyond Neurocognitive Disorders

Sim¹,

Chan²

2017

J AIDS Clin Res

View full text Add to dashboard Cite

Objective: To illustrate clinical challenges, explore existing literature and identify knowledge gaps in the management of neuropsychiatric issues beyond neurocognitive disorders in HIV patients. Methods:Three case vignettes from a consultation-liaison psychiatry setting in a general hospital were collated and summarised into a case series. Clinical questions were identified from each vignette and pertinent literature reviewed to aid a further discussion of management issues. Results:The first case vignette discusses the potential of a multi-dimensional approach to the formulation of a HIV patient with emergent psychiatric and cognitive symptoms. In the second, pharmacological treatment of a HIV patient with a severe manic relapse of Bipolar 1 Disorder and active TB disease is discussed. Lastly, the collective effects of severe Traumatic Brain Injury (TBI) and HIV infection superimposed on that of an ageing brain are described. Iatrogenic risks of polypharmacy in an elderly HIV patient are further explored. Conclusion:The practical aspects of clinical challenges regarding the management of HIV patients are multi-fold and most apparent in a real-world setting. Existing literature does not yet adequately address the diagnostic dilemmas and pharmacological complexities faced. The management of other neuropsychiatric manifestations in a HIV patient remains a crucial field to be explored.

show abstract

Neurocognitive Change in the Era of HIV Combination Antiretroviral Therapy: The Longitudinal CHARTER Study

Abstract: NC change is common in HIV infection and appears to be driven by a complex set of risk factors involving HIV disease, its treatment, and comorbid conditions.

Cited by 352 publications

References 27 publications

Prevalence of HIV-associated neurocognitive disorders in the Multicenter AIDS Cohort Study

Prevalence of HIV-associated neurocognitive disorders in the Multicenter AIDS Cohort Study

Evaluation of Three Brief Screening Tests for Older Patients with Mild HIVAssociated Neurocognitive Disorders in the cART Era

Neuropsychiatric Complexities in the HIV Patient – Clinical Challenges beyond Neurocognitive Disorders

Contact Info

Product

Resources

About